Journal
SKELETAL MUSCLE
Volume 2, Issue -, Pages -Publisher
BIOMED CENTRAL LTD
DOI: 10.1186/2044-5040-2-24
Keywords
Stem cells; Mesoangioblasts; Hydrogel; Muscular dystrophy; Muscle regeneration; Cell therapy; Tissue engineering
Categories
Funding
- Fondazione Roma
- Telethon
- Duchenne Parent Project Italia
- EC-IP FP7 grant Angioscaff
- EC-IP FP7 grant Biodesign
- EC-IP FP7 grant Optistem
- Medical Research Council [MR/J006785/1] Funding Source: researchfish
- MRC [MR/J006785/1] Funding Source: UKRI
Ask authors/readers for more resources
Background: Cell-transplantation therapies have attracted attention as treatments for skeletal-muscle disorders; however, such research has been severely limited by poor cell survival. Tissue engineering offers a potential solution to this problem by providing biomaterial adjuvants that improve survival and engraftment of donor cells. Methods: In this study, we investigated the use of intra-muscular transplantation of mesoangioblasts (vessel-associated progenitor cells), delivered with an injectable hydrogel biomaterial directly into the tibialis anterior (TA) muscle of acutely injured or dystrophic mice. The hydrogel cell carrier, made from a polyethylene glycol-fibrinogen (PF) matrix, is polymerized in situ together with mesoangioblasts to form a resorbable cellularized implant. Results: Mice treated with PF and mesoangioblasts showed enhanced cell engraftment as a result of increased survival and differentiation compared with the same cell population injected in aqueous saline solution. Conclusion: Both PF and mesoangioblasts are currently undergoing separate clinical trials: their combined use may increase chances of efficacy for localized disorders of skeletal muscle.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available